Actively Recruiting
A Cohort Study in Newly Diagnosed MZL
Led by Fudan University · Updated on 2025-11-19
2500
Participants Needed
1
Research Sites
526 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.
CONDITIONS
Official Title
A Cohort Study in Newly Diagnosed MZL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Newly diagnosed with marginal zone lymphoma by histopathology within the past 6 months
- No prior anti-tumor therapy including chemotherapy, radiotherapy, or immunotherapy
- Willing to provide biological samples such as blood and tumor tissue
- Voluntarily agree to join the study and sign informed consent
- Willing to accept long-term follow-up
You will not qualify if you...
- HIV infection
- Unable to attend regular hospital follow-up visits
- Presence of other medical conditions and speech impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
R
Rong Tao, M.D
CONTACT
Y
Yizhen Liu, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here